Amoy Diagnostics (300685.SZ): has obtained the invention patent certificate.

Gelonghui, on December 13th, announced that Amoy Diagnostics (300685.SZ) recently received an invention patent certificate issued by the Japan Patent Office. The patent is titled "Probe primer set for detecting gene mutations in myeloid leukemia based on high-throughput sequencing and its application," with patent number 7591097, classified as an invention. The patent rights are valid for twenty years from the date of application, and the patent holder is the company.

Gelonghui FinanceDec 13 16:28

Express News | A former employee of Amoy Diagnostics has been sentenced to prison for being involved in a fraud case with AstraZeneca employees.

BreakingsDec 12 12:15

PD-L1 Tests Market Research Report 2024, Featuring F. Hoffmann-La Roche, Agilent Technologies, Amoy Diagnostics, BioGenex Laboratories - Segments, Share, Regulatory, Reimbursement and Forecast to 2036 - ResearchAndMarkets.com

BusinesswireDec 5 21:19

Amoy Diagnostics (300685.SZ): has repurchased 1.17% of the shares.

Soochow Securities, November 4th | Amoy Diagnostics (300685.SZ) announced that as of October 31, 2024, the company implemented the repurchase of 4,666,240 shares through a special securities account for centralized auction trading method, accounting for 1.17% of the company's current total share capital. The highest fill price for repurchased shares was 21.91 yuan/share, and the lowest fill price was 17.20 yuan/share, with a total amount paid of 85,835,044.00 yuan (excluding transaction costs). This repurchase complies with the company's established share repurchase program and relevant legal requirements.

Gelonghui FinanceNov 4 16:56

Express News | The social security fund held positions with a market cap of nearly 190 billion yuan at the end of the third quarter.

BreakingsOct 31 07:37

Amoy Diagnostics (300685): Significant growth in Q3 24, with many indications of diagnostic products approved in Japan.

Event: The company released the third quarter report for 2024, achieving revenue of 0.305 billion yuan, a year-on-year increase of 22.53%; achieving net income attributable to the parent company of 0.083 billion yuan, a year-on-year increase of 77.58%; achieving non-net income attributable to the parent company.

everbrightOct 29 16:46